Clinical trials: Neoplasm, Experimental
Melanoma
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.
- Trial name
- NCT04303169
- Testing
- Pembrolizumab, Vibostolimab, Gebasaxturev
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 146 people
- Sponsor
- Merck Sharp & Dohme LLC
Colonoscopy, Looping
Experimental Device to Improve Colonoscopy
This study will test the use of a new device called a segmental stiffening wire (SSW) in colonoscopy to correct a problem called looping.
- Conditions
- Colonoscopy, Looping, Prevent Looping, Colon Cancer Screening
- Trial name
- NCT00719641
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Oesophageal Squamous Cell Carcinoma
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC).
- Trial name
- NCT07405151
- Testing
- I-DXd, Rescue Medication
- Where
- 32 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasms, Breast Cancer
An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related protein (PTHrP) when compared to zoledronic acid…
- Conditions
- Breast Neoplasms, Breast Cancer, Metastasis
- Trial name
- NCT00051779
- Testing
- CAL
- Where
- 38 sites in United States
- Sponsor
- Chugai Pharma USA
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Intraepithelial Neoplasia
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)
If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study.
- Trial name
- NCT00028353
- Testing
- GTX-006 (Acapodene)
- Where
- 25 sites in United States
- Volunteers
- 500 people
- Sponsor
- GTx
Lymphedema, Malignant Neoplasm
Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
This phase 1-2 trial studies the side effects and the best dose of recombinant human hyaluronidase and to see how well it works in treating lymphedema in patients with cancer.
- Trial name
- NCT01928030
- Testing
- recombinant human hyaluronidase
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Gastric Cancer, Cancer of the Stomach
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction…
- Conditions
- Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
- Trial name
- NCT03704077
- Testing
- Relatlimab + Nivolumab, Nivolumab, Paclitaxel
- Where
- 84 sites in United States, Argentina and 12 more
- Sponsor
- Bristol-Myers Squibb
Cancer
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer
The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.
- Trial name
- NCT03351231
- Testing
- BMS-986242, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer…
- Trial name
- NCT07079631
- Testing
- BNT314, Pumitamig, SoC chemotherapy treatment 1
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 482 people
- Sponsor
- BioNTech SE
Cancer
Development and Validation of a Patient Reported Experience Measure for Experimental Cancer Medicine
This is a four stage, non-interventional study to develop and pilot test a Patient Reported Experience Measure (PREM) in experimental cancer medicine trials.
- Trial name
- PREM-ECM (NCT05386602)
- Where
- United Kingdom
- Volunteers
- 570 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic Lung Cancer, Metastatic Lung Cancer With ALK/ROS1 Fusion
Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway
Targeted cancer therapies have a higher therapeutic index than chemotherapy and are prescribed to tens of thousands of patients in France each year.
- Trial name
- DRACONIS (NCT06781905)
- Testing
- Assessments of neuropsychiatric, neurocognitive and psychosocial alterations
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Carcinoma, Renal Cell
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy.
- Trial name
- NCT05287945
- Testing
- Orellanine
- Where
- 10 sites in United States, France and 3 more
- Volunteers
- 75 people
- Sponsor
- Oncorena AB
Advanced Cancer
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.
- Trial name
- CheckMate 577 (NCT02743494)
- Testing
- Nivolumab
- Where
- 204 sites in United States, Argentina and 29 more
- Volunteers
- 794 people
- Sponsor
- Bristol-Myers Squibb
Cancer
Tumour Characterisation to Guide Experimental Targeted Therapy - National
The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumour DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the…
- Trial name
- NCT04723316
- Where
- 20 sites in United Kingdom
- Volunteers
- 6,000 people
- Sponsor
- The Christie NHS Foundation Trust
Advanced Solid Tumor
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in…
- Trial name
- NCT06589596
- Testing
- BGB-58067, BG-89894, Standard of Care Therapy
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 695 people
- Sponsor
- BeOne Medicines
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography [PET]/magnetic resonance imaging [MRI]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT05376878
- Testing
- Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Melanoma, Malignant Melanoma
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Background: Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors.
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
- Trial name
- NCT00513604
- Testing
- aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Small Cell Lung Carcinoma
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC…
- Trial name
- NCT04938817
- Testing
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830
- Where
- 48 sites in United States, Australia and 10 more
- Volunteers
- 110 people
- Sponsor
- Merck Sharp & Dohme LLC